E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Published on 11/21/2005 in the Prospect News Bank Loan Daily, Prospect News Biotech Daily and Prospect News High Yield Daily.

Moody's confirms Fresenius

Moody's Investors Service said it confirmed all ratings of Fresenius AG, concluding the rating review initiated on Oct. 14.

The outlook is stable for the company's corporate family rating of Ba2 and €300 million senior notes rated Ba2.

Moody's said the ratings confirmation reflects the strategic rationale for the acquisition of Helios and expected benefits to the Fresenius group in terms of a significantly improved market position in the hospital sector in Germany, an opportunity to accelerate the turnaround at ProServe and further diversification of the group's revenue and cash flow generation.

However, Moody's noted that the group's corporate family rating is weakly positioned in the Ba2 category as a result of its increased appetite for large scale M&A as evidenced over the past several months combined with an increase in acquisition-related debt.


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.